These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 5651509)

  • 21. Biochemical correlates of behavior in schizophrenic patients. Schizophrenic patients receiving tryptophan and methionine or methionine together with a monoamine oxidase inhibitor.
    Berlet HH; Matsumoto K; Pscheidt GR; Spaide J; Bull C; Himwich HE
    Arch Gen Psychiatry; 1965 Dec; 13(6):521-31. PubMed ID: 5841751
    [No Abstract]   [Full Text] [Related]  

  • 22. Plasma amino acids in schizophrenic patients with methionine or cysteine loading and a monoamine oxidase inhibitor.
    Spaide JK; Davis JM; Himwich HE
    Am J Clin Nutr; 1971 Sep; 24(9):1053-9. PubMed ID: 5094479
    [No Abstract]   [Full Text] [Related]  

  • 23. 3:4-Dimethoxyphenylethylamine, a normal or abnormal metabolite?
    Narasimhachari N; Plaut J; Himwich HE
    J Psychiatr Res; 1972 Dec; 9(4):325-8. PubMed ID: 4664953
    [No Abstract]   [Full Text] [Related]  

  • 24. The administration of methionine to chronic schizophrenic patients: a review of ten studies.
    Cohen SM; Nichols A; Wyatt R; Pollin W
    Biol Psychiatry; 1974 Apr; 8(2):209-25. PubMed ID: 4601948
    [No Abstract]   [Full Text] [Related]  

  • 25. Biochemical research in schizophrenia.
    Boulton AA
    Nature; 1971 May; 231(5297):22-8. PubMed ID: 4930468
    [No Abstract]   [Full Text] [Related]  

  • 26. Mono-amine oxidase inhibitors and schizophrenia.
    Price J; Hopkinson G
    Psychiatr Clin (Basel); 1968; 1(2):65-84. PubMed ID: 4878603
    [No Abstract]   [Full Text] [Related]  

  • 27. [Tryptaminuria and urinary 5-H.I.A.A. in neuropsychiatry (preliminary note)].
    Bourgeois M; Henry P
    Ann Med Psychol (Paris); 1967 Oct; 125(3):Suppl 2:440-6. PubMed ID: 6081829
    [No Abstract]   [Full Text] [Related]  

  • 28. [Disturbances of tryptophan metabolism during methionine and nialamide administration in chronic schizophrenic patients].
    Rosengarten H; Stencka K; Kowalska K; Wardaszko-Lyskowska H; Szemis A; Wlosińska I; Krzyzowski J; Jus A
    Psychiatr Pol; 1970; 4(3):261-8. PubMed ID: 5459695
    [No Abstract]   [Full Text] [Related]  

  • 29. [Cerebral biochemical disorders and mental diseases. A propos of the "pink spot"].
    Delay J; Boissier JR; Deniker P; Simon P; Ginestet D; Wirz-Justice A
    Encephale; 1969; 58(4):360-76. PubMed ID: 5378191
    [No Abstract]   [Full Text] [Related]  

  • 30. Correlations between behavior of schizophrenic patients and the urinary excretions of indoles, catechols and steroids.
    Himwich HE
    Folia Psychiatr Neurol Jpn; 1965; 19(4):326-45. PubMed ID: 5899882
    [No Abstract]   [Full Text] [Related]  

  • 31. Inhibition of monoamine oxidase in man by furazolidone.
    Pettinger WA; Soyangco FG; Oates JA
    Clin Pharmacol Ther; 1968; 9(4):442-7. PubMed ID: 5655478
    [No Abstract]   [Full Text] [Related]  

  • 32. Biological heterogeneity in schizophrenic patients.
    Buchsbaum MS; Davis GC
    Am J Psychiatry; 1979 Dec; 136(12):1618. PubMed ID: 292318
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of a selective inhibitor of type A monoamine oxidase--Lilly 51641--on behavior, sleep and circadian rhythms in depressed and schizophrenic patients.
    Carman JS; Gillin JC; Murphy DL; Weinberger DR; Kleinman JE; Bigelow LB; Wyatt RJ
    Commun Psychopharmacol; 1978; 2(6):513-23. PubMed ID: 371909
    [No Abstract]   [Full Text] [Related]  

  • 34. Influence of treatment with an amino oxidase inhibitor on the excretion of bufotenin and the clinical symptoms in chronic schizophrenic patients.
    Heller B
    Int J Neuropsychiatry; 1966 Apr; 2(2):193-203. PubMed ID: 5959966
    [No Abstract]   [Full Text] [Related]  

  • 35. Urinary tryptamine excretion in chronic schizophrenics with low platelet MAO activity.
    Sullivan JL; Coffey CE; Basuk B; Cavenar JO; Maltbie AA; Zung WW
    Biol Psychiatry; 1980 Feb; 15(1):113-20. PubMed ID: 7357050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kinetic studies and effects in vivo of a new monoamine oxidase inhibitor, N-[2-(o-chlorophenoxy)-ethyl]-cyclopropylamine.
    Fuller RW
    Biochem Pharmacol; 1968 Oct; 17(10):2097-106. PubMed ID: 5696879
    [No Abstract]   [Full Text] [Related]  

  • 37. Biochemistry and pharmacology of tryptamines and beta-carbolines. A minireview.
    McKenna DJ; Towers GH
    J Psychoactive Drugs; 1984; 16(4):347-58. PubMed ID: 6394730
    [No Abstract]   [Full Text] [Related]  

  • 38. Urinary acid metabolites of biogenic amines in schizophrenic patients.
    Domino EF
    Schizophr Bull; 1980; 6(2):238-44. PubMed ID: 6154967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors affecting the urinary excretion of endogenously formed dimethyltryptamine in normal human subjects.
    Oon MC; Murray RM; Rodnight R; Murphy MP; Birley JL
    Psychopharmacology (Berl); 1977 Oct; 54(2):171-5. PubMed ID: 22091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Adrenergic amines and monoaminoxidases in essential arterial hypertension].
    Sicuteri F; Buffoni F; Michelacci S; Del Bene E
    Acta Vitaminol Enzymol; 1969; 23(1):45-63. PubMed ID: 4896867
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.